A "revolutionary" new treatment to lower cholesterol will be made available to thousands of patients through the National Health Service (NHS) following a “world-leading deal” announced this week.
The game-changing drug, inclisiran, is delivered as an injection twice a year and can be used alongside statins, adding to the options available to patients to help control their cholesterol levels. The NHS says it has been estimated that inclisiran could prevent 55,000 heart attacks and strokes, saving 30,000 lives within the next decade. Its deal with Swiss pharmaceutical major Novartis means around 300,000 patients with high cholesterol and a history of cardiovascular disease can benefit from the lifesaving drug over the next three years, a figure that could rise to nearly half a million people beyond that initial period.
"The NHS is committed to using cutting-edge treatments to save and improve patients’ lives,” said Amanda Pritchard, chief executive of the NHS.
MORE LIKE THIS…
“Heart disease is still one of the major killer conditions so it is fantastic that we now have such an effective and convenient treatment for those living with dangerously high cholesterol levels. This world-leading deal for the rollout of inclisiran will save lives and enable hundreds of thousands of people to benefit from this revolutionary treatment, while also being fair to taxpayers,” she said.
More than two in five people in England have high cholesterol which puts them at significant risk of developing heart disease, and around 6.5 million adults in England are currently taking lipid-lowering drugs such as statins. The NHS said it is rolling the injection out at unprecedented scale because the health service and manufacturer have concluded a deal that enables the NHS to utilise inclisiran at an affordable and cost effective price.
"With heart disease being the number one cause of death globally, we've worked with the NHS to respond to this urgent need with pioneering solutions that can deliver rapid access to innovative medicines at scale,” said Vas Narasimhan, the Global Indian CEO of Novartis.
MORE LIKE THIS…
"Solutions like this can't be implemented by one entity alone, and we're proud to collaborate with the NHS on a concerted effort that could potentially revolutionise the way society approaches the treatment of cardiovascular disease," he said.
Heart disease is the world’s biggest killer and annually accounts for around a quarter of deaths in England, with 140,000 people dying from the condition each year.